Global News

Halloran Consulting Group adds CMO Mark Weinberg

Tuesday, January 12, 2016

Halloran Consulting Group has expanded its strategic capabilities with the addition of Mark Weinberg, M.D., MBA, who will serve as chief medical officer (CMO) and managing director. The addition of Weinberg to Halloran’s advisory services creates a unique offering to life sciences companies seeking CMO expertise as a key part of an on-demand, integrated development team.

[Read More]

Celgene announces exec changes, including Hugan and executive chairman

Tuesday, January 12, 2016

Celgene has announced organizational changes that will position the company for continued long-term growth, effective March 1. Bob Hugin will serve as executive chairman. Hugin will continue to lead the board of directors and manage the strategic direction of the company. Mark Alles will be promoted to chief executive officer. Jacqualyn Fouse, Ph.D., will be promoted to president and chief operating officer. Scott Smith, president of immunology and inflammation, will assume an expanded leadership role.

[Read More]

Sanofi, Warp Drive Bio to collaborate on oncology and antibiotics

Tuesday, January 12, 2016

Sanofi and Warp Drive Bio, a privately held biotechnology company using the molecules and mechanisms of nature to discover and develop transformative medicines, have extended and reshaped their existing collaboration utilizing Warp Drive’s proprietary SMART (Small Molecule Assisted Receptor Targeting) and Genome Mining platforms to discover novel oncology therapeutics and antibiotics.

[Read More]

Shire and Baxalta to combine, with a rare disease focus

Tuesday, January 12, 2016

Shire and Baxalta have reached an agreement to combine. Baxalta shareholders will receive $18 in cash and 0.1482 Shire ADS per Baxalta share. Based on Shire’s closing ADS price on January 8, 2016, this implies a total current value of $45.57 per Baxalta share, representing an aggregate consideration of approximately $32 billion. The exchange ratio is based on Shire’s 30-day trading day volume weighted average ADS price of $199.03 as of Jan. 8, which implies a total value of $47.50 per Baxalta share.

[Read More]

C4 Therapeutics collaborates in the new field of TPD therapeutics

Monday, January 11, 2016

C4 Therapeutics will enter into a strategic collaboration with Roche to develop novel treatments in the field of targeted protein degradation (TPD) using C4’s Degronimid technology. C4’s Degronimids represent a new class of small molecules, TPD therapeutics, which target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the ubiquitin/proteasome system (UPS).

[Read More]